Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AT&T Inc. (T) vs GeneDx Holdings Corp (WGS) Price & Performance

AT&T Inc.Trade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

AT&T Inc. vs GeneDx Holdings Corp — how do they compare? AT&T Inc. trades at $22.23 (market cap $152.52B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: AT&T Inc. is far larger — about 84.7× GeneDx Holdings Corp's market cap, and AT&T Inc. pays a 5.06% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

TWGS
Market Cap
$152.52B$1.80B
Sector
MediaTechnology
52-Week High
$29.62$167.51
52-Week Low
$20.49$34.51
Enterprise Value
$297.87B$1.80B
Dividend Yield
5.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AT&T Inc.

AT&T (T) trades at $22.26, up 2.13% with a bullish technical signal despite mixed moving averages. The stock shows strong fundamentals with a low P/E of 7.39, robust profitability margins (net margin 16.94%), and consistent earnings beats in recent quarters. Recent cash flow improvement to $15.12B in 2025 and declining debt-to-asset ratio to 32.59% in 2024 signal financial health. The company faces competitive pressures in telecom but benefits from fiber expansion and stable wireless pricing.

Outlook remains positive with analyst consensus target of $25.61 offering 15% upside. Key opportunities include dividend yield support and fiber growth, while risks involve intense telecom competition and potential earnings volatility. Wall Street sentiment is cautiously optimistic with 41% buy ratings, though technical indicators show some overbought conditions near-term.

GeneDx Holdings Corp

GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.

Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AT&T Inc.

AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.

Read more on T

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS